A careful delineation of markers of embryonic cell pathways will create a map of the embryome that will facilitate the purification of many therapeutically-useful cell types. The identification of specific therapeutic cell lines will, in turn, help ensure that future cell-based therapies are safe and unlikely to suffer serious side effects, such as tumor formation.
EMERYVILLE, Calif. (PRWEB) December 18, 2007
"Human embryonic stem cells have enormous potential in medicine due to their ability to become all of the cell types of the human body," said Michael West, Ph.D., Chief Executive Officer of BioTime. "A careful delineation of markers of embryonic cell pathways will create a map of the embryome that will facilitate the purification of many therapeutically-useful cell types. The identification of specific therapeutic cell lines will, in turn, help ensure that future cell-based therapies are safe and unlikely to suffer serious side effects, such as tumor formation."
The relational database will be built using core software licensed, on an exclusive basis for this purpose, from Targeted Therapeutics Consulting, Inc., which currently operates a relational database for cancer therapy research and the development of anti-cancer drugs. When the new embryome database is operational, Embryome Sciences will provide researchers access to it through an internet website. Embryome Sciences plans to launch this new website early next year beginning with a database map of the embryome of the mouse, and plans to add the human embryome by June 2008.
In addition to providing access to its embryome database, Embryome Sciences' new website may also be used to market stem cell research products developed by Embryome Sciences and by other companies.
Other products that Embryome Sciences plans to develop include growth and differentiation factors that can be used to induce embryonic stem cells to become desired cell types, and a line of purification tools useful to researchers in purification and quality control analysis of products in regenerative medicine.
BioTime believes that the development of products such as these in the Embryomics(TM) sector may allow Embryome Sciences to commercialize products more quickly, using less capital, than developing therapeutic products from stem cells. Embryome Sciences' plan is to market its products and services to companies and academic researchers, such as those working under the $3 billion California stem cell initiative, in this growing industry, and to provide them the tools they need to attain their goals.
About BioTime, Inc.
BioTime, headquartered in Emeryville, California, develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions, and technology for use in surgery, emergency trauma treatment and other applications. BioTime's lead product Hextend is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ Corp. under exclusive licensing agreements. BioTime has recently entered the field of regenerative medicine through its wholly owned subsidiary Embryome Sciences, Inc. where it plans to develop new medical and research products using embryonic stem cell technology. Information about BioTime can be found on the web at http://www.biotimeinc.com. Hextend(R), PentaLyte(R), HetaCool(R), and Embryomics(TM) are trademarks of BioTime, Inc.
About Targeted Therapeutics Consulting, Inc.
Targeted Therapeutics Consulting (TTC), a Mill Valley, California-based company, has created a unique information platform and project management tool for cancer drug development professionals in industry and academia. Subscription to TTC's proprietary database provides access to comprehensive information relevant to drug development in oncology and related information on tumor biology. TTC utilizes its web-based information technology to provide individualized consulting solutions. TTC also provides partner companies with relational database solutions for capturing and analyzing biological and clinical trial data. TTC will continue expanding its services to other areas of medicine. Information about TTC is available on the web at http://www.targetedtherapeutics.com or by phone at (415) 388-5954.
Forward Looking Statements
The matters discussed in this press release include forward-looking statements which are subject to various risks, uncertainties, and other factors that could cause actual results to differ materially from the results anticipated. Such risks and uncertainties include but are not limited to the success of BioTime in developing new stem cell products and technologies; results of clinical trials of BioTime products; the ability of BioTime and its licensees to obtain additional FDA and foreign regulatory approval to market BioTime products; competition from products manufactured and sold or being developed by other companies; the price of and demand for BioTime products, and the ability of BioTime to raise the capital needed to finance its current and planned operations. Other factors that could affect BioTime's operations and financial condition are discussed in BioTime's Annual Report on Form 10-KSB filed with the Securities and Exchange Commission.
Click here to join our email alert list.